Evidence map›Paper›PMID 30954703›Full record

ArticleNeurobiology of disease2019

An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2.

Natalie Connor-Robson, Heather Booth, Jeffrey G Martin, Benbo Gao, Kejie Li, Natalie Doig, Jane Vowles, Cathy Browne, Laura Klinger, Peter Juhasz and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Neurobiology of disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Cell-Free DNA and Mitochondria in Parkinson's Disease.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Proteomic insights into the biology of dopaminergic neurons.Frontiers in molecular neuroscience · 2025
    Review
  12. Article
  13. Review
  14. Cell type-specific functions of Alzheimer's disease endocytic risk genes.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Natalie Connor-RobsonOxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. Electronic address: natalie.connor-robson@dpag.ox.ac.uk.
Heather BoothOxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
Jeffrey G MartinBiogen, Cambridge, MA, USA. Electronic address: jeff.martin@biogen.com.
Benbo GaoBiogen, Cambridge, MA, USA. Electronic address: benbo.gao@biogen.com.
Kejie LiBiogen, Cambridge, MA, USA. Electronic address: kejie.li@biogen.com.
Natalie DoigMedical Research Council Brain Network Dynamics Unit, University of Oxford, Oxford, UK. Electronic address: natalie.doig@pharm.ox.ac.uk.
Jane VowlesJames Martin Stem Cell Facility, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.; Oxford Parkinson's Disease Centre (OPDC), Oxford, UK. Electronic address: jane.vowles@path.ox.ac.uk.
Cathy BrowneJames Martin Stem Cell Facility, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.. Electronic address: cathy.browne@path.ox.ac.uk.
Laura KlingerOxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. Electronic address: laura.klinger@imc-krems.eu.
Peter JuhaszBiogen, Cambridge, MA, USA.
Christine KleinInstitute of Neurogenetics, University of Leubeck, Maria-Goeppert-Str. 1, 23562 Luebeck, Germany.. Electronic address: christine.klein@neuro.uni-luebeck.de.
Sally A CowleyJames Martin Stem Cell Facility, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.; Oxford Parkinson's Disease Centre (OPDC), Oxford, UK. Electronic address: sally.cowley@path.ox.ac.uk.
Paul BolamMedical Research Council Brain Network Dynamics Unit, University of Oxford, Oxford, UK; Oxford Parkinson's Disease Centre (OPDC), Oxford, UK. Electronic address: paul.bolam@pharm.ox.ac.uk.
Warren HirstBiogen, Cambridge, MA, USA. Electronic address: warren.hirst@biogen.com.
Richard Wade-MartinsOxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. Electronic address: richard.wade-martins@dpag.ox.ac.uk.
University of Oxford · GBBiogen (United States) · USInstitute for Integrative and Experimental Genomics · DE

Funding

Medical Research Council MC_EX_MR/N50192X/1Medical Research Council MC_UU_12024/2Medical Research Council MR/L023784/1Medical Research Council MR/L023784/2Medical Research Council MR/M024962/1Parkinson's UK H-1102Parkinson's UK J-0901Wellcome Trust 101821
6 · The paper itself

Abstract

backgroundMutations in LRRK2 are the most common cause of autosomal dominant Parkinson's disease, and the relevance of LRRK2 to the sporadic form of the disease is becoming ever more apparent. It is therefore essential that studies are conducted to improve our understanding of the cellular role of this protein. Here we use multiple models and techniques to identify the pathways through which LRRK2 mutations may lead to the development of Parkinson's disease.

methodsA novel integrated transcriptomics and proteomics approach was used to identify pathways that were significantly altered in iPSC-derived dopaminergic neurons carrying the LRRK2-G2019S mutation. Western blotting, immunostaining and functional assays including FM1-43 analysis of synaptic vesicle endocytosis were performed to confirm these findings in iPSC-derived dopaminergic neuronal cultures carrying either the LRRK2-G2019S or the LRRK2-R1441C mutation, and LRRK2 BAC transgenic rats, and post-mortem human brain tissue from LRRK2-G2019S patients.

resultsOur integrated -omics analysis revealed highly significant dysregulation of the endocytic pathway in iPSC-derived dopaminergic neurons carrying the LRRK2-G2019S mutation. Western blot analysis confirmed that key endocytic proteins including endophilin I-III, dynamin-1, and various RAB proteins were downregulated in these cultures and in cultures carrying the LRRK2-R1441C mutation, compared with controls. We also found changes in expression of 25 RAB proteins. Changes in endocytic protein expression led to a functional impairment in clathrin-mediated synaptic vesicle endocytosis. Further to this, we found that the endocytic pathway was also perturbed in striatal tissue of aged LRRK2 BAC transgenic rats overexpressing either the LRRK2 wildtype, LRRK2-R1441C or LRRK2-G2019S transgenes. Finally, we found that clathrin heavy chain and endophilin I-III levels are increased in human post-mortem tissue from LRRK2-G2019S patients compared with controls.

conclusionsOur study demonstrates extensive alterations across the endocytic pathway associated with LRRK2 mutations in iPSC-derived dopaminergic neurons and BAC transgenic rats, as well as in post-mortem brain tissue from PD patients carrying a LRRK2 mutation. In particular, we find evidence of disrupted clathrin-mediated endocytosis and suggest that LRRK2-mediated PD pathogenesis may arise through dysregulation of this process.

Indexed as

MutationAnimalsDopaminergic NeuronsEndocytosisGene Expression ProfilingHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2ProteomicsRatsRats, TransgenicSynaptic VesiclesLeucine-Rich Repeat Serine-Threonine Protein Kinase-2ClathrinEndocytosisEndophilinLRRK2Parkinson's diseaseRabs

Identifiers

PMID30954703
PMCPMC6597903
OpenAlexW2931260132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.